\BOOKMARK [1][-]{section.1}{Cover}{}% 1
\BOOKMARK [2][-]{subsection.1.1}{Identifikasjon}{section.1}% 2
\BOOKMARK [2][-]{subsection.1.2}{Dato}{section.1}% 3
\BOOKMARK [2][-]{subsection.1.4}{Har signert samtykke til studiedeltakelse}{section.1}% 4
\BOOKMARK [2][-]{subsection.1.5}{Protokollen skal legges inn i forskningsdatabase}{section.1}% 5
\BOOKMARK [1][-]{section.2}{Denne bolken gjelder kun dersom personen ogs\345 skal inkluderes i en forskningsstudie}{}% 6
\BOOKMARK [2][-]{subsection.2.1}{Person-ID}{section.2}% 7
\BOOKMARK [2][-]{subsection.2.2}{Protokoll vidersendt til studieansvarlig}{section.2}% 8
\BOOKMARK [2][-]{subsection.2.3}{Annen ID}{section.2}% 9
\BOOKMARK [2][-]{subsection.2.4}{Deltakers initialer}{section.2}% 10
\BOOKMARK [2][-]{subsection.2.5}{Deltatt i intervensjonsstudie}{section.2}% 11
\BOOKMARK [2][-]{subsection.2.6}{Dersom deltatt i intervensjonsstudie}{section.2}% 12
\BOOKMARK [2][-]{subsection.2.7}{Sted}{section.2}% 13
\BOOKMARK [2][-]{subsection.2.8}{Testleder \(TL\)}{section.2}% 14
\BOOKMARK [2][-]{subsection.2.9}{Inklusjonsgruppe}{section.2}% 15
\BOOKMARK [2][-]{subsection.2.10}{Rekrutteringsmetode}{section.2}% 16
\BOOKMARK [2][-]{subsection.2.11}{Henvisnings\345rsak}{section.2}% 17
\BOOKMARK [2][-]{subsection.2.12}{Ev. kommentar}{section.2}% 18
\BOOKMARK [1][-]{section.3}{Baseline info}{}% 19
\BOOKMARK [2][-]{subsection.3.1}{Kj\370nn}{section.3}% 20
\BOOKMARK [2][-]{subsection.3.2}{H\345ndbruk}{section.3}% 21
\BOOKMARK [2][-]{subsection.3.3}{F\370dsels\345r \(19XX\)}{section.3}% 22
\BOOKMARK [2][-]{subsection.3.5}{Nasjonalitet}{section.3}% 23
\BOOKMARK [2][-]{subsection.3.6}{Yrker, tidligere/n\345v\346rende}{section.3}% 24
\BOOKMARK [2][-]{subsection.3.7}{Antall \345rs utdanning fra og med skolestart}{section.3}% 25
\BOOKMARK [2][-]{subsection.3.9}{Sett kryss for h\370yeste fullf\370rte utdannelsesniv\345}{section.3}% 26
\BOOKMARK [2][-]{subsection.3.10}{Ekteskapsstatus:}{section.3}% 27
\BOOKMARK [2][-]{subsection.3.11}{Ant. barn}{section.3}% 28
\BOOKMARK [2][-]{subsection.3.13}{Sivilstatus: Bor med samboer/ektefelle?}{section.3}% 29
\BOOKMARK [2][-]{subsection.3.14}{Bor personen med mindre\345rige barn?}{section.3}% 30
\BOOKMARK [2][-]{subsection.3.15}{Bosituasjon}{section.3}% 31
\BOOKMARK [2][-]{subsection.3.16}{Kommunale tiltak}{section.3}% 32
\BOOKMARK [2][-]{subsection.3.17}{Kj\370rer deltaker bil?}{section.3}% 33
\BOOKMARK [2][-]{subsection.3.18}{Yrkesaktiv?}{section.3}% 34
\BOOKMARK [2][-]{subsection.3.19}{Kognitive symptomer/demens}{section.3}% 35
\BOOKMARK [2][-]{subsection.3.20}{Vaskul\346r sykdom}{section.3}% 36
\BOOKMARK [2][-]{subsection.3.21}{Parkinson's sykdom}{section.3}% 37
\BOOKMARK [2][-]{subsection.3.22}{Antall affiserte i familien}{section.3}% 38
\BOOKMARK [2][-]{subsection.3.23}{Tremor}{section.3}% 39
\BOOKMARK [2][-]{subsection.3.24}{Antall affiserte i familien}{section.3}% 40
\BOOKMARK [2][-]{subsection.3.25}{Annen relevant sykdom}{section.3}% 41
\BOOKMARK [2][-]{subsection.3.26}{Utdypende opplysninger, n\370yaktig diagnose, andre slektninger med demenssykdom}{section.3}% 42
\BOOKMARK [1][-]{section.4}{BASELINE SYKEHISTORIE FRA PASIENT}{}% 43
\BOOKMARK [2][-]{subsection.4.1}{Verken kognitive eller fysiske symptomer \(gjelder kontrollpersoner uten symptomer\), g\345 til seksjon 5}{section.4}% 44
\BOOKMARK [2][-]{subsection.4.3}{Hvilket symptom merket pasienten f\370rst endring i:}{section.4}% 45
\BOOKMARK [2][-]{subsection.4.4}{Hvilken side av kroppen merket du f\370rste symptomene}{section.4}% 46
\BOOKMARK [2][-]{subsection.4.5}{Alder for diagnosen}{section.4}% 47
\BOOKMARK [2][-]{subsection.4.7}{Debut}{section.4}% 48
\BOOKMARK [2][-]{subsection.4.8}{Utvikling siden starten}{section.4}% 49
\BOOKMARK [2][-]{subsection.4.9}{Hvis forverring, har dette skjedd}{section.4}% 50
\BOOKMARK [2][-]{subsection.4.10}{N\345v\346rende symptomer}{section.4}% 51
\BOOKMARK [2][-]{subsection.4.11}{Svikt i ADL}{section.4}% 52
\BOOKMARK [2][-]{subsection.4.12}{Fysiske symptomer}{section.4}% 53
\BOOKMARK [2][-]{subsection.4.13}{Hvis ja p\345 falltendens:}{section.4}% 54
\BOOKMARK [2][-]{subsection.4.14}{Hvor lenge har du hatt ufrivillige bevegelser?}{section.4}% 55
\BOOKMARK [2][-]{subsection.4.15}{S\370vn}{section.4}% 56
\BOOKMARK [2][-]{subsection.4.16}{Psykiske symptomer}{section.4}% 57
\BOOKMARK [2][-]{subsection.4.17}{Dersom hallusinasjoner, spesifis\351r}{section.4}% 58
\BOOKMARK [2][-]{subsection.4.18}{Kommentarer}{section.4}% 59
\BOOKMARK [1][-]{section.5}{TIDLIGERE SYKDOMMER}{}% 60
\BOOKMARK [2][-]{subsection.5.1}{Sykdommer i CNS}{section.5}% 61
\BOOKMARK [2][-]{subsection.5.2}{Hjerte-karsykdom}{section.5}% 62
\BOOKMARK [2][-]{subsection.5.3}{Metabolske sykdommer}{section.5}% 63
\BOOKMARK [2][-]{subsection.5.4}{Betydelig sansesvekkelse}{section.5}% 64
\BOOKMARK [2][-]{subsection.5.5}{Behandlingstrengende psykiatrisk lidelse}{section.5}% 65
\BOOKMARK [2][-]{subsection.5.6}{Andre tilstander av betydning for det aktuelle}{section.5}% 66
\BOOKMARK [1][-]{section.6}{AKTUELL MEDIKASJON}{}% 67
\BOOKMARK [2][-]{subsection.6.1}{Har du opplevd god effekt av medisiner?}{section.6}% 68
\BOOKMARK [2][-]{subsection.6.2}{Har du merket impulsivitets bivirkninger?}{section.6}% 69
\BOOKMARK [2][-]{subsection.6.3}{Levodopa ekvivalente d\370gndoser}{section.6}% 70
\BOOKMARK [2][-]{subsection.6.4}{DBS \345rstall}{section.6}% 71
\BOOKMARK [2][-]{subsection.6.5}{Duodopa pumpe \345rstall}{section.6}% 72
\BOOKMARK [2][-]{subsection.6.6}{Lecigon pumpe \345rstall}{section.6}% 73
\BOOKMARK [2][-]{subsection.6.7}{Apomorfin pumpe \345rstall}{section.6}% 74
\BOOKMARK [2][-]{subsection.6.8}{Full liste over medisiner, kommentarer}{section.6}% 75
\BOOKMARK [1][-]{section.7}{STIMULANTIA}{}% 76
\BOOKMARK [2][-]{subsection.7.1}{R\370yking?}{section.7}% 77
\BOOKMARK [2][-]{subsection.7.2}{Evt kommentar. Dersom tidligere r\370yker: n\345r sluttet personen \345 r\370yke.}{section.7}% 78
\BOOKMARK [2][-]{subsection.7.4}{Overforbruk av alkohol, medisiner, andre rusmidler. Utf\370r FAST sp\370rreskjema dersom mer enn 6 enheter for kvinner og 8 enheter for menn}{section.7}% 79
\BOOKMARK [2][-]{subsection.7.5}{Evt kommentar}{section.7}% 80
\BOOKMARK [1][-]{section.8}{NATURLIGE FUNKSJONER}{}% 81
\BOOKMARK [1][-]{section.9}{GDS}{}% 82
\BOOKMARK [2][-]{subsection.9.1}{GDS 15 total score}{section.9}% 83
\BOOKMARK [2][-]{subsection.9.3}{GDS 30 total score}{section.9}% 84
\BOOKMARK [1][-]{section.10}{SOMATISK STATUS}{}% 85
\BOOKMARK [2][-]{subsection.10.1}{Blodtrykk, liggende, etter ett minutt}{section.10}% 86
\BOOKMARK [2][-]{subsection.10.5}{Blodtrykk, st\345ende, umiddelbart etter \345 ha reist seg}{section.10}% 87
\BOOKMARK [2][-]{subsection.10.9}{Blodtrykk, st\345ende, etter ett minutt}{section.10}% 88
\BOOKMARK [2][-]{subsection.10.13}{Blodtrykk, st\345ende, etter tre minutter}{section.10}% 89
\BOOKMARK [2][-]{subsection.10.17}{Puls; regelmessig}{section.10}% 90
\BOOKMARK [2][-]{subsection.10.18}{Ortostatisk hypotensjon}{section.10}% 91
\BOOKMARK [2][-]{subsection.10.19}{Bradykardi}{section.10}% 92
\BOOKMARK [2][-]{subsection.10.20}{Pasientens h\370yde i cm}{section.10}% 93
\BOOKMARK [2][-]{subsection.10.22}{Pasientens vekt i kg}{section.10}% 94
\BOOKMARK [2][-]{subsection.10.24}{Har du hatt vekttap siste \345ret?}{section.10}% 95
\BOOKMARK [2][-]{subsection.10.25}{Hvor mange kg har du g\345tt ned i vekt?}{section.10}% 96
\BOOKMARK [2][-]{subsection.10.26}{Timed up and go, noter gjennomsnitt av to fors\370k}{section.10}% 97
\BOOKMARK [1][-]{section.11}{BASELINE SYKEHISTORIE FRA P\305R\330RENDE}{}% 98
\BOOKMARK [2][-]{subsection.11.1}{Innhenting av informasjon fra p\345r\370rende skal gj\370res, ble det gjort?}{section.11}% 99
\BOOKMARK [2][-]{subsection.11.2}{Relasjon til deltaker}{section.11}% 100
\BOOKMARK [2][-]{subsection.11.3}{Kontakthyppighet}{section.11}% 101
\BOOKMARK [2][-]{subsection.11.4}{Evt spesielle momenter fra p\345 r\370rendesamtale/generell kommentar om evt mental endring}{section.11}% 102
\BOOKMARK [2][-]{subsection.11.6}{Hvis ja, p\345 f\370rste sp\370rsm\345l: Hvilke symptom merket p\345r\370rende f\370rst: Endring i:}{section.11}% 103
\BOOKMARK [2][-]{subsection.11.8}{Debut}{section.11}% 104
\BOOKMARK [2][-]{subsection.11.9}{Utvikling siden starten}{section.11}% 105
\BOOKMARK [2][-]{subsection.11.10}{Hvis forverring, har dette skjedd}{section.11}% 106
\BOOKMARK [2][-]{subsection.11.12}{Svikt i ADL}{section.11}% 107
\BOOKMARK [2][-]{subsection.11.13}{Fysiske symptomer}{section.11}% 108
\BOOKMARK [2][-]{subsection.11.14}{Psykiske symptomer}{section.11}% 109
\BOOKMARK [2][-]{subsection.11.15}{Dersom hallusinasjoner, spesifis\351r}{section.11}% 110
\BOOKMARK [2][-]{subsection.11.17}{Kommentarer}{section.11}% 111
\BOOKMARK [2][-]{subsection.11.18}{Kommentarer}{section.11}% 112
\BOOKMARK [1][-]{section.12}{IQCODE \205 Sp\370rreskjema til p\345r\370rende}{}% 113
\BOOKMARK [1][-]{section.13}{Belastningsskala \205 p\345r\370rende}{}% 114
\BOOKMARK [1][-]{section.14}{MMSE - NR}{}% 115
\BOOKMARK [2][-]{subsection.14.1}{Total score}{section.14}% 116
\BOOKMARK [1][-]{section.15}{CERAD ORDLISTE}{}% 117
\BOOKMARK [2][-]{subsection.15.1}{FORS\330K 1 SUM}{section.15}% 118
\BOOKMARK [2][-]{subsection.15.2}{FORS\330K 2 SUM}{section.15}% 119
\BOOKMARK [2][-]{subsection.15.3}{FORS\330K 3 SUM}{section.15}% 120
\BOOKMARK [2][-]{subsection.15.4}{Innl\346ring}{section.15}% 121
\BOOKMARK [2][-]{subsection.15.6}{GJENKALLING 1 SUM}{section.15}% 122
\BOOKMARK [1][-]{section.16}{KLOKKETEST}{}% 123
\BOOKMARK [1][-]{section.17}{VOSP Silhouettes}{}% 124
\BOOKMARK [2][-]{subsection.17.1}{Total score}{section.17}% 125
\BOOKMARK [1][-]{section.18}{TRAIL-MAKING TEST}{}% 126
\BOOKMARK [2][-]{subsection.18.1}{Tid del A \(sekunder\)}{section.18}% 127
\BOOKMARK [2][-]{subsection.18.3}{Number of mistakes \(A\)}{section.18}% 128
\BOOKMARK [2][-]{subsection.18.5}{Tid del B \(sekunder\)}{section.18}% 129
\BOOKMARK [2][-]{subsection.18.7}{Number of mistakes \(B\)}{section.18}% 130
\BOOKMARK [1][-]{section.19}{COWAT - FAS}{}% 131
\BOOKMARK [2][-]{subsection.19.1}{Antall korrekte ord, f\370rste bokstav}{section.19}% 132
\BOOKMARK [2][-]{subsection.19.2}{Antall korrekte ord, andre bokstav}{section.19}% 133
\BOOKMARK [2][-]{subsection.19.3}{Antall korrekte ord, tredje bokstav}{section.19}% 134
\BOOKMARK [2][-]{subsection.19.4}{Totalt antall korrekte ord}{section.19}% 135
\BOOKMARK [1][-]{section.20}{MOCA}{}% 136
\BOOKMARK [2][-]{subsection.20.1}{Total score}{section.20}% 137
\BOOKMARK [1][-]{section.21}{KLINISK UNDERS\330KELSE}{}% 138
\BOOKMARK [2][-]{subsection.21.1}{Somatisk unders\370kelse?}{section.21}% 139
\BOOKMARK [2][-]{subsection.21.2}{Nevrologisk unders\370kelse?}{section.21}% 140
\BOOKMARK [1][-]{section.22}{Motorisk UPDRS}{}% 141
\BOOKMARK [2][-]{subsection.22.2}{Total}{section.22}% 142
\BOOKMARK [1][-]{section.23}{MDS CLINICAL DIAGNOSTIC CRITERIA FOR PD}{}% 143
\BOOKMARK [2][-]{subsection.23.1}{Does the patient have parkinsosnism as defined by the MDS criteria}{section.23}% 144
\BOOKMARK [2][-]{subsection.23.2}{Are any absolute exclusion criteria present?}{section.23}% 145
\BOOKMARK [2][-]{subsection.23.3}{Number of red flags present}{section.23}% 146
\BOOKMARK [2][-]{subsection.23.4}{Number of supportive criteria present}{section.23}% 147
\BOOKMARK [2][-]{subsection.23.5}{Are there at least 2 supportive criteria and no red flags?}{section.23}% 148
\BOOKMARK [2][-]{subsection.23.6}{Are there more than 2 red flags?}{section.23}% 149
\BOOKMARK [2][-]{subsection.23.7}{Is the number of red flags equal to or less than the number of supportive criteria}{section.23}% 150
\BOOKMARK [1][-]{section.24}{KDV: KLINISK DEMENSVURDERING}{}% 151
\BOOKMARK [2][-]{subsection.24.1}{Hukommelse}{section.24}% 152
\BOOKMARK [2][-]{subsection.24.2}{Orienteringsevne}{section.24}% 153
\BOOKMARK [2][-]{subsection.24.3}{Vurderingsevne}{section.24}% 154
\BOOKMARK [2][-]{subsection.24.4}{Samfunnsaktiviteter}{section.24}% 155
\BOOKMARK [2][-]{subsection.24.5}{Hjem og fritidsinteresser}{section.24}% 156
\BOOKMARK [2][-]{subsection.24.6}{Egenomsorg}{section.24}% 157
\BOOKMARK [2][-]{subsection.24.7}{Total KDV \(evt kan f\370lgende nettside brukes: http://www.biostat.wustl.edu/ adrc/cdrpgm/\)}{section.24}% 158
\BOOKMARK [1][-]{section.25}{Stadieklassifisering}{}% 159
\BOOKMARK [1][-]{section.26}{Oppsummering av unders\370kelser}{}% 160
\BOOKMARK [2][-]{subsection.26.1}{MR hode}{section.26}% 161
\BOOKMARK [2][-]{subsection.26.3}{Parakliniske unders\370kelser}{section.26}% 162
\BOOKMARK [2][-]{subsection.26.4}{CSF}{section.26}% 163
\BOOKMARK [1][-]{section.27}{Etiologisk diagnose}{}% 164
\BOOKMARK [2][-]{subsection.27.1}{Diagnose}{section.27}% 165
\BOOKMARK [2][-]{subsection.27.2}{Alzheimers sykdom etiology}{section.27}% 166
\BOOKMARK [2][-]{subsection.27.3}{Vaskul\346r kognitiv svikt}{section.27}% 167
\BOOKMARK [2][-]{subsection.27.4}{Lewy legeme sykdom}{section.27}% 168
\BOOKMARK [2][-]{subsection.27.5}{Frontotemporal degenerasjon}{section.27}% 169
\BOOKMARK [2][-]{subsection.27.6}{Blandet etiologi}{section.27}% 170
\BOOKMARK [2][-]{subsection.27.7}{Parkinsonisme}{section.27}% 171
\BOOKMARK [2][-]{subsection.27.8}{Annen diagnose,}{section.27}% 172
\BOOKMARK [2][-]{subsection.27.9}{Angi annen diagnose:}{section.27}% 173
\BOOKMARK [2][-]{subsection.27.10}{Evt kommentar ang\345ende diagnose}{section.27}% 174
\BOOKMARK [2][-]{subsection.27.11}{Blir subjektet ekskludert?}{section.27}% 175
\BOOKMARK [2][-]{subsection.27.12}{Dato for eksklusjon}{section.27}% 176
\BOOKMARK [2][-]{subsection.27.14}{Eksklusjonsgrunn}{section.27}% 177
